I am not an expert on big pharma but I would hate for our 2RT product to partner with a pharma group with an interest in the antiVEGF area. They would put it on the shelf and stall it. I am sure our management are alert enough to see this. With the figures mentioned it’s a great opportunity for a mid sized pharma company to become a major by partnering with EYE and selling to the world . The FDA and governments worldwide could save hundreds of billions by reducing the need for antiVEGF injections. The US insurance companies would be rubbing their hands.
Nova Eye Medical (EYE) Discussion, page-1798
-
- There are more pages in this discussion • 1,390 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.025(11.9%) |
Mkt cap ! $53.82M | |||
| Open | High | Low | Value | Volume |
| 21.5¢ | 23.5¢ | 21.5¢ | $94.36K | 411.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 45769 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 73449 | 2 |
View Market Depth
| Last trade - 16.10pm 14/08/2024 (20 minute delay) ? |
| EYE (ASX) Chart |